These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice. Qiao Y, Wang J, Karagoz E, Liang B, Song X, Shang R, Evert K, Xu M, Che L, Evert M, Calvisi DF, Tao J, Wang B, Monga SP, Chen X. Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831 [Abstract] [Full Text] [Related]
6. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling. Wang W, Li S, Liu P, Sideras K, van de Werken HJG, van der Heide M, Cao W, Lavrijsen M, Peppelenbosch MP, Bruno M, Pan Q, Smits R. Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989 [Abstract] [Full Text] [Related]
7. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM, Lu FM. World J Gastroenterol; 2015 May 28; 21(20):6317-28. PubMed ID: 26034368 [Abstract] [Full Text] [Related]
8. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. Kim YD, Park CH, Kim HS, Choi SK, Rew JS, Kim DY, Koh YS, Jeung KW, Lee KH, Lee JS, Juhng SW, Lee JH. J Gastroenterol Hepatol; 2008 Jan 28; 23(1):110-8. PubMed ID: 18171349 [Abstract] [Full Text] [Related]
9. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P, Perret C. Oncogene; 2007 Feb 01; 26(5):774-80. PubMed ID: 16964294 [Abstract] [Full Text] [Related]
10. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC. Charawi S, Just PA, Savall M, Abitbol S, Traore M, Metzger N, Ravinger R, Cavard C, Terris B, Perret C. J Pathol; 2019 Apr 01; 247(4):435-443. PubMed ID: 30566242 [Abstract] [Full Text] [Related]
11. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. Liang B, Zhou Y, Qian M, Xu M, Wang J, Zhang Y, Song X, Wang H, Lin S, Ren C, Monga SP, Wang B, Evert M, Chen Y, Chen X, Huang Z, Calvisi DF, Chen X. J Hepatol; 2021 Jul 01; 75(1):120-131. PubMed ID: 33577921 [Abstract] [Full Text] [Related]
12. Conditional disruption of Axin1 leads to development of liver tumors in mice. Feng GJ, Cotta W, Wei XQ, Poetz O, Evans R, Jardé T, Reed K, Meniel V, Williams GT, Clarke AR, Dale TC. Gastroenterology; 2012 Dec 01; 143(6):1650-9. PubMed ID: 22960659 [Abstract] [Full Text] [Related]
13. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. Nat Genet; 2000 Mar 01; 24(3):245-50. PubMed ID: 10700176 [Abstract] [Full Text] [Related]
14. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. Delgado E, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, Zhang Y, Monga SP. J Hepatol; 2015 Feb 01; 62(2):380-7. PubMed ID: 25457204 [Abstract] [Full Text] [Related]
15. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Oncogene; 2002 Jul 18; 21(31):4863-71. PubMed ID: 12101426 [Abstract] [Full Text] [Related]
16. Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B virus-related hepatocellular carcinoma and overexpression of AXIN1 induces apoptosis in hepatocellular cancer cells. Li J, Quan H, Liu Q, Si Z, He Z, Qi H. Oncol Res; 2013 Jul 18; 20(7):281-8. PubMed ID: 23879168 [Abstract] [Full Text] [Related]
17. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis. Kim W, Khan SK, Gvozdenovic-Jeremic J, Kim Y, Dahlman J, Kim H, Park O, Ishitani T, Jho EH, Gao B, Yang Y. J Clin Invest; 2017 Jan 03; 127(1):137-152. PubMed ID: 27869648 [Abstract] [Full Text] [Related]
18. Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines. Zhang R, Li S, Schippers K, Eimers B, Niu J, Hornung BVH, van den Hout MCGN, van Ijcken WFJ, Peppelenbosch MP, Smits R. PLoS One; 2024 Jan 03; 19(6):e0304607. PubMed ID: 38848383 [Abstract] [Full Text] [Related]
19. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Clin Cancer Res; 2012 Sep 15; 18(18):4997-5007. PubMed ID: 22811581 [Abstract] [Full Text] [Related]